NEW YORK (GenomeWeb) – Rosetta Genomics announced today that it has agreed to acquire CynoGen, a molecular diagnostics laboratory doing business as PersonalizeDx, for $2 million in cash plus stock.

Through the deal, Rosetta will pick up PersonalizeDx's portfolio of proprietary fluorescence in situ hybridization-based tests for prostate, bladder, and lung cancers, as well as a CLIA lab in Lake Forest, Calif.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

In Science this week: International Wheat Genome Sequencing Consortium publishes the bread wheat cultivar Chinese Spring reference genome, and more.

At his FDA Law Blog, Jeffrey Gibbs discusses FDA's technical assistance for the draft Diagnostic Accuracy and Innovation Act.

The New York Times reports that genetic testing has uncovered unfaithful penguins at a Utah aquarium.

Cancer researcher loses funding under new Wellcome Trust anti-bullying policies, the Guardian reports.